EXTON, Pa., July 16, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) announced today that the company will host a 'Teach-in' on cytomegalovirus (CMV) infection at the Plaza Hotel in New York City at 5:00 P.M. Eastern Time on July 21, 2004. At the meeting, transplant physicians and members of senior management will provide an overview of CMV in the immunocompromised and transplant setting, the challenges of managing patients at risk of CMV infection, currently available treatments, the opportunities for new therapies, and an overview of maribavir, ViroPharma's leading clinical candidate molecule that inhibits CMV.
Investors and the general public may access the live audio webcast of the meeting and a downloadable version of the slides via the ViroPharma corporate website, www.viropharma.com. Windows Media or Real Player will be needed to access the live webcast and archive of the audio presentation. The archive of the meeting will be available until August 20, 2004.
Maribavir is a benzimidazole compound being studied for the prevention and treatment of cytomegalovirus (CMV) infections. ViroPharma licensed maribavir from GlaxoSmithKline (GSK) in August 2003. Prior to that date, maribavir had been administered orally to 100 human subjects in several GSK Phase 1 studies.
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma is currently focused on drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV).